AVBP: ArriVent Corp P/S Multiple

Symbol and logo of brand ArriVent Corp (AVBP)

ArriVent BioPharma, Inc (AVBP) is minimizing regulatory risks by expanding its oncology programs in Asia and the US. The price/sales ratio trend clearly demonstrates market valuation volatility, while the 133.70 value captures the metric level. High clinical trial costs are temporarily limiting operating profit, and fierce competition from pharmaceutical market leaders creates significant challenges for the implementation of the new inhibitor.

AVBP: arrivent.com Price-to-Revenue Ratio 11/11/2026 - 11/13/2026

ArriVent (AVBP) - metric breakdowns and financial figures

- share price and consensus valuation forecast:
Price Performance Chart ArriVent BioPharma, Inc.|AVBP - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization ArriVent|AVBP - Total Company Value
- balance sheet equity data:
Accounting Value of a Share ArriVent BioPharma|AVBP - Company Book Value|Market Value to Book Value arrivent.com|AVBP - Company Total Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Coefficient ArriVent BioPharma, Inc|AVBP - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity ArriVent Corp|AVBP - Company Aggregate Debts|Debts to Book Value ArriVent|AVBP - Company Long-Term Debt|Company Short-Term Indebtedness ArriVent BioPharma|Intermediate Liquidity Ratio arrivent.com
- earnings and valuation multiples information:
AVBP - Net Income|Expected Net Income ArriVent BioPharma, Inc|AVBP - P/E Multiple|Future Price to Earnings ArriVent BioPharma|AVBP - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio ArriVent|AVBP - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months ArriVent BioPharma|AVBP - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months arrivent.com|AVBP - Earnings growth in current year|Expected earnings per share trend next year ArriVent BioPharma, Inc
- total revenue and sales volume data:
AVBP - Revenue and Sales Volume|Projected Sales Volume ArriVent|AVBP - Price-to-Revenue Ratio|Forward Price to Sales ArriVent
General company analysis:AVBP - arrivent.com
Core merchandise of ArriVent Corp

For the biotechnology sector, where ArriVent BioPharma, Inc (AVBP) focuses on the expansion of EGFR therapy in the US and China, the price-to-sales ratio reflects market expectations for the commercialization of furmonertinib. The trend in the company's average P/S compares the current business value with sales volume, allowing investors to identify periods of unjustified overvaluation or the undervaluation of clinical success potential.

Competitors of ArriVent BioPharma, Inc

LTRN (lanternpharma.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple BIAF (bioAffinity Technologies, Inc.)|P/S Multiple eEFFECTOR Therapeutics, Inc. EFTR